1 |
(11c)pe2i |
- |
- |
- |
- |
006 1件: 6 💬 |
2 |
(2-chloro-5-[11c]methoxy-n-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) |
- |
- |
- |
- |
006 1件: 6 💬 |
3 |
(3beta, 5beta, 25r)-spirostan-3-ol |
- |
- |
- |
- |
006 1件: 6 💬 |
4 |
(3ß, 5ß, 25r)-spirostan-3-ol |
- |
- |
- |
- |
006 1件: 6 💬 |
5 |
(6s)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol |
- |
- |
- |
- |
006 1件: 6 💬 |
6 |
(minus)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate |
- |
- |
- |
- |
006 1件: 6 💬 |
7 |
(r)-troloxamide quinone |
- |
- |
- |
- |
006 1件: 6 💬 |
8 |
(s)- 2- amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol |
- |
- |
- |
- |
006 1件: 6 💬 |
9 |
(s)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate |
- |
- |
- |
- |
006 1件: 6 💬 |
10 |
0 mg tropicamide |
Tropicamide |
1件: D00397 D00397 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
11 |
0.04 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
12 |
0.08 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
13 |
0.2 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
14 |
0.3 mg tropicamide |
Tropicamide |
1件: D00397 D00397 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
15 |
0.4 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
16 |
0.6 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
17 |
0.8 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
18 |
0.9% sodium chloride |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
006 4件: 6, 14, 51, 53 💬 |
19 |
0.9% sodium chloride (normal saline) |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
006 1件: 6 💬 |
20 |
00000 |
- |
- |
- |
- |
006 1件: 6 💬 |
21 |
000000 |
- |
- |
- |
- |
006 1件: 6 💬 |
22 |
009-0 |
- |
- |
- |
- |
006 1件: 6 💬 |
23 |
009-1 |
- |
- |
- |
- |
006 1件: 6 💬 |
24 |
009-2 |
- |
- |
- |
- |
006 1件: 6 💬 |
25 |
009-3 |
- |
- |
- |
- |
006 1件: 6 💬 |
26 |
009-4 |
- |
- |
- |
- |
006 1件: 6 💬 |
27 |
009-5 |
- |
- |
- |
- |
006 1件: 6 💬 |
28 |
009-a0 |
- |
- |
- |
- |
006 1件: 6 💬 |
29 |
009-a1 |
- |
- |
- |
- |
006 1件: 6 💬 |
30 |
009-a2 |
- |
- |
- |
- |
006 1件: 6 💬 |
31 |
009-a3 |
- |
- |
- |
- |
006 1件: 6 💬 |
32 |
1 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
33 |
1 mg qd to 7 mg qd pf-06649751 (if de-escalated in parent study) |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
34 |
1 mg tropicamide |
Tropicamide |
1件: D00397 D00397 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
35 |
1. tesofensine (ns 2330) |
Tesofensine |
- |
- |
- |
006 1件: 6 💬 |
36 |
1.0 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
37 |
1.0 mg rasagiline mesylate |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
38 |
1.2 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
39 |
100 |
- |
- |
- |
- |
006 2件: 6, 97 💬 |
40 |
11c-methylreboxetine |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
41 |
11c-pbr28 |
- |
- |
- |
- |
006 2件: 6, 13 💬 |
42 |
11c-pib |
- |
- |
- |
- |
006 2件: 6, 13 💬 |
43 |
11c-raclopride |
Raclopride |
- |
- |
- |
006 1件: 6 💬 |
44 |
125 |
- |
- |
- |
- |
006 1件: 6 💬 |
45 |
13n-ammonia |
Ammonia |
1件: D02916 D02916 💬 |
- |
- |
006 2件: 6, 17 💬 |
46 |
15 mg qd de-escalated to 7 mg qd pf-06649751 in parent study remain at 7 mg qd |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
47 |
15 mg qd pf-06649751 |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
48 |
15o h2o |
- |
- |
- |
- |
006 1件: 6 💬 |
49 |
18-fdtbz |
- |
- |
- |
- |
006 1件: 6 💬 |
50 |
18f florbetaben |
- |
- |
- |
- |
006 1件: 6 💬 |
51 |
18f- dtbz |
- |
- |
- |
- |
006 1件: 6 💬 |
52 |
18f-av-133 |
Florbenazine F-18 |
- |
- |
- |
006 1件: 6 💬 |
53 |
18f-av-45 |
- |
- |
- |
- |
006 2件: 6, 127 💬 |
54 |
18f-dopa |
- |
- |
- |
- |
006 3件: 6, 17, 75 💬 |
55 |
18f-dopa pet |
- |
- |
- |
- |
006 1件: 6 💬 |
56 |
18f-dopamne |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
57 |
18f-dtbz |
- |
- |
- |
- |
006 1件: 6 💬 |
58 |
18f-dtbz av-133 |
- |
- |
- |
- |
006 1件: 6 💬 |
59 |
18f-fdg |
Fludeoxyglucose (18F) |
- |
- |
- |
005 12件: 5, 6, 7, 13, 41, 46, 53, 84, 85, 96, 127, 300 💬 |
60 |
1[(6- allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- |
- |
- |
- |
- |
006 1件: 6 💬 |
61 |
1[(6- allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea |
- |
- |
- |
- |
006 1件: 6 💬 |
62 |
1[(6- allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- |
- |
- |
- |
- |
006 1件: 6 💬 |
63 |
1[(6- allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea |
- |
- |
- |
- |
006 1件: 6 💬 |
64 |
2 mg perampanel |
Perampanel |
1件: D08964 D08964 💬 |
GRIA1 4件: GRIA1, GRIA2, GRIA3, GRIA4 💬 |
Amphetamine addiction 16件: Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway |
006 1件: 6 💬 |
65 |
2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide |
- |
- |
- |
- |
006 1件: 6 💬 |
66 |
2-[[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]-4- piperidinyl]-5-oxo-2-pyrrolidinyl]carbonyl]amino]- n,n,6-trimethyl-4-pyridinecarboxamide,dihydrochloride |
- |
- |
- |
- |
006 2件: 6, 162 💬 |
67 |
200 mg bia 6-512 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
68 |
207-3120 |
- |
- |
- |
- |
006 1件: 6 💬 |
69 |
240mg amantadine hcl er tablets |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
70 |
25 mg bia9 1067 |
- |
- |
- |
- |
006 1件: 6 💬 |
71 |
25 mg ongentys |
- |
- |
- |
- |
006 1件: 6 💬 |
72 |
25330 |
- |
- |
- |
- |
006 1件: 6 💬 |
73 |
3 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
74 |
3 mg qd to 7 mg qd pf-06649751 (de-escalated in parent study) |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
75 |
3 mg tropicamide |
Tropicamide |
1件: D00397 D00397 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
76 |
3- (9,10- didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate |
- |
- |
- |
- |
006 1件: 6 💬 |
77 |
3-(3,4-dihydroxyphenyl)-l-alanine |
Alanine |
1件: D00012 D00012 💬 |
- |
- |
006 1件: 6 💬 |
78 |
320mg amantadine hcl er tablets |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
79 |
4 mg perampanel |
Perampanel |
1件: D08964 D08964 💬 |
GRIA1 4件: GRIA1, GRIA2, GRIA3, GRIA4 💬 |
Amphetamine addiction 16件: Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway |
006 1件: 6 💬 |
80 |
50 mg bia 9 1067 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
81 |
50 mg ongentys |
- |
- |
- |
- |
006 1件: 6 💬 |
82 |
6abeta - apomorphine-10,11-diol hydrochloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
83 |
6aß - apomorphine-10,11-diol hydrochloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
84 |
7 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
85 |
7 mg qd to 7 mg qd pf-06649751 (de-escalated in parent study) |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
86 |
7-beta-hydroxyepiandrosterone |
7-beta-Hydroxyepiandrosterone |
- |
- |
- |
006 1件: 6 💬 |
87 |
75 |
- |
- |
- |
- |
006 1件: 6 💬 |
88 |
8-ohdg |
8-hydroxy-2'-deoxyguanosine |
- |
- |
- |
006 1件: 6 💬 |
89 |
[11c]pbr28 |
- |
- |
- |
- |
006 1件: 6 💬 |
90 |
[11c]pxt012253 |
- |
- |
- |
- |
006 1件: 6 💬 |
91 |
[11c]smw139 |
- |
- |
- |
- |
006 1件: 6 💬 |
92 |
[123i] 5-ia |
- |
- |
- |
- |
006 1件: 6 💬 |
93 |
[123i] ibvm and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
94 |
[123i] mzint injection and serial dynamic spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
95 |
[123i]-ibvm |
- |
- |
- |
- |
006 1件: 6 💬 |
96 |
[123i]b-cit |
- |
- |
- |
- |
006 1件: 6 💬 |
97 |
[123i]b-cit spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
98 |
[123i]beta cit |
- |
- |
- |
- |
006 1件: 6 💬 |
99 |
[123i]beta cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
100 |
[123i]beta-cit |
- |
- |
- |
- |
006 1件: 6 💬 |
101 |
[123i]beta-cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
102 |
[123i]clinde |
- |
- |
- |
- |
006 2件: 6, 13 💬 |
103 |
[123i]mni-420 |
- |
- |
- |
- |
006 2件: 6, 8 💬 |
104 |
[123i]ß cit |
- |
- |
- |
- |
006 1件: 6 💬 |
105 |
[123i]ß cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
106 |
[123i]ß-cit |
- |
- |
- |
- |
006 1件: 6 💬 |
107 |
[123i]ß-cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
108 |
[14c]-bia 9-1067 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
109 |
[15o]h2o |
- |
- |
- |
- |
006 1件: 6 💬 |
110 |
[18f] cfpypb |
- |
- |
- |
- |
006 1件: 6 💬 |
111 |
[18f] lbt-999 |
- |
- |
- |
- |
006 1件: 6 💬 |
112 |
[18f] lbt-999 pet |
- |
- |
- |
- |
006 1件: 6 💬 |
113 |
[18f] pbr06 |
- |
- |
- |
- |
006 2件: 6, 13 💬 |
114 |
[18f]-(e)-n-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane |
- |
- |
- |
- |
006 1件: 6 💬 |
115 |
[18f]-feppa |
- |
- |
- |
- |
006 2件: 6, 13 💬 |
116 |
[18f]dpa-714 pet scan |
- |
- |
- |
- |
006 1件: 6 💬 |
117 |
[18f]fdopa |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
118 |
[18f]fdopa pet/ct |
- |
- |
- |
- |
006 1件: 6 💬 |
119 |
[18f]fe-pe2i |
- |
- |
- |
- |
006 1件: 6 💬 |
120 |
[18f]fpeb |
- |
- |
- |
- |
006 3件: 6, 8, 206 💬 |
121 |
[18f]mk-9470 |
- |
- |
- |
- |
006 1件: 6 💬 |
122 |
[18f]mni-1126 |
- |
- |
- |
- |
006 1件: 6 💬 |
123 |
[18f]mppf |
- |
- |
- |
- |
006 1件: 6 💬 |
124 |
[18f]nos |
- |
- |
- |
- |
006 1件: 6 💬 |
125 |
[18f]p17-059 |
- |
- |
- |
- |
006 1件: 6 💬 |
126 |
[18f]pi-2620 |
- |
- |
- |
- |
006 2件: 6, 127 💬 |
127 |
[18f]t807 ([18f]mni-777) |
- |
- |
- |
- |
005 2件: 5, 6 💬 |
128 |
[21cfr640.30] plasma from 18 - 25 year old volunteer donors |
- |
- |
- |
- |
006 1件: 6 💬 |
129 |
[abbv-951] |
- |
- |
- |
- |
006 1件: 6 💬 |
130 |
[f-18] fluorodopa positron emission tomography |
- |
- |
- |
- |
006 1件: 6 💬 |
131 |
[jnj31-31001074] |
- |
- |
- |
- |
006 1件: 6 💬 |
132 |
[na] |
- |
- |
- |
- |
006 7件: 6, 11, 35, 46, 53, 65, 299 💬 |
133 |
A-dopamine |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
134 |
Aav2-gdnf |
- |
- |
- |
- |
006 1件: 6 💬 |
135 |
Ab1010 |
- |
- |
- |
- |
002 6件: 2, 5, 6, 13, 46, 96 💬 |
136 |
Abbv-0805 |
- |
- |
- |
- |
006 1件: 6 💬 |
137 |
Abbv-951 |
- |
- |
- |
- |
006 1件: 6 💬 |
138 |
Abt-slv187 |
- |
- |
- |
- |
006 1件: 6 💬 |
139 |
Acamprosate |
Acamprosate |
2件: D02780 D02780, D07058 D07058 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 2件: 6, 206 💬 |
140 |
Accordion pill carbidopa/levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
141 |
Accordion pill ¿ carbidopa/levodopa 50/400 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
142 |
Accordion pill ¿ carbidopa/levodopa 50/500 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
143 |
Accordion pill? carbidopa/levodopa 50/400 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
144 |
Accordion pill? carbidopa/levodopa 50/500 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
145 |
Accordion pill™ carbidopa/levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
146 |
Accordion pill™ carbidopa/levodopa 50/400 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
147 |
Accordion pill™ carbidopa/levodopa 50/500 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
148 |
Acetate |
Acetate |
- |
- |
- |
001 43件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 227, 235, 265, 288, 298, 299 💬 |
149 |
Acetylcysteine |
Acetylcysteine |
1件: D00221 D00221 💬 |
- |
- |
006 16件: 6, 13, 19, 20, 34, 49, 51, 58, 85, 94, 111, 164, 193, 233, 298, 299 💬 |
150 |
Acp-103 |
- |
- |
- |
- |
006 1件: 6 💬 |
151 |
Acr325 |
ACR325 |
- |
- |
- |
006 1件: 6 💬 |
152 |
Active comparator |
- |
- |
- |
- |
006 2件: 6, 46 💬 |
153 |
Active drug (biib014) at 10, 30, 100, or 300 mg once daily. |
- |
- |
- |
- |
006 1件: 6 💬 |
154 |
Active drug: pimavanserin 17mg (2 strength tablets) |
Pimavanserin |
- |
- |
- |
006 1件: 6 💬 |
155 |
Active investigational treatment ent-01 |
- |
- |
- |
- |
006 1件: 6 💬 |
156 |
Ad-810n (zonisamide) |
Zonisamide |
1件: D00538 D00538 💬 |
CACNA1G 8件: CACNA1G, CACNA1H, CACNA1I, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 11件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dopaminergic synapse, GnRH secretion, MAPK signaling pathway, Taste transduction, Type II diabetes mellitus |
006 1件: 6 💬 |
157 |
Adjuvant without active component |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
158 |
Administration of stable isotope-labelled leucine- |
Leucine |
1件: D00030 D00030 💬 |
- |
- |
006 1件: 6 💬 |
159 |
Ads-5102 |
- |
- |
- |
- |
006 2件: 6, 13 💬 |
160 |
Ads-5102 (extended release amantadine hcl) |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
161 |
Adx48621 |
- |
- |
- |
- |
006 1件: 6 💬 |
162 |
Affitope® pd01a |
- |
- |
- |
- |
006 1件: 6 💬 |
163 |
Affitope® pd01a + adjuvant |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
164 |
Afq056 |
- |
- |
- |
- |
006 3件: 6, 8, 206 💬 |
165 |
Afq056 with l-dopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
166 |
Afq065 |
- |
- |
- |
- |
006 1件: 6 💬 |
167 |
Agomelatine |
Agomelatine |
1件: D02578 D02578 💬 |
HTR2C 3件: HTR2C, MTNR1A, MTNR1B 💬 |
Calcium signaling pathway 6件: Calcium signaling pathway, Circadian entrainment, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
006 1件: 6 💬 |
168 |
Agomelatine or piacebo |
Agomelatine |
1件: D02578 D02578 💬 |
HTR2C 3件: HTR2C, MTNR1A, MTNR1B 💬 |
Calcium signaling pathway 6件: Calcium signaling pathway, Circadian entrainment, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
006 1件: 6 💬 |
169 |
Aha |
- |
- |
- |
- |
006 1件: 6 💬 |
170 |
Akst4290 |
- |
- |
- |
- |
006 2件: 6, 162 💬 |
171 |
Al |
- |
- |
- |
- |
005 9件: 5, 6, 7, 28, 51, 67, 86, 114, 127 💬 |
172 |
Alanine |
Alanine |
1件: D00012 D00012 💬 |
- |
- |
006 4件: 6, 13, 298, 299 💬 |
173 |
Allogeneic bone marrow-derived mscs (1 x 10 6 msc/kg) |
- |
- |
- |
- |
006 1件: 6 💬 |
174 |
Allogeneic bone marrow-derived mscs (10 x 10 6 msc/kg) |
- |
- |
- |
- |
006 1件: 6 💬 |
175 |
Allogeneic bone marrow-derived mscs (3 x 10 6 msc/kg) |
- |
- |
- |
- |
006 1件: 6 💬 |
176 |
Allogeneic bone marrow-derived mscs (6 x 10 6 msc/kg) |
- |
- |
- |
- |
006 1件: 6 💬 |
177 |
Allopurinol |
Allopurinol |
1件: D00224 D00224 💬 |
XDH 1件: XDH 💬 |
Caffeine metabolism 5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
006 6件: 6, 46, 57, 66, 96, 97 💬 |
178 |
Altropane |
Altropane |
- |
- |
- |
006 1件: 6 💬 |
179 |
Altropane® |
Altropane |
- |
- |
- |
006 1件: 6 💬 |
180 |
Amantadin-ratiopharm 100mg |
- |
- |
- |
- |
006 1件: 6 💬 |
181 |
Amantadine |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 4件: 6, 8, 13, 127 💬 |
182 |
Amantadine 300 mg |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
183 |
Amantadine hcl er |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
184 |
Amantadine hcl extended release |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
185 |
Amantadine hcl extended release capsule |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
186 |
Amantadine hydrochloride |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
187 |
Amantadine hydrochloride (hcl) |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
188 |
Amantadine sulfate |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
189 |
Ambrosan 60mg tablets |
- |
- |
- |
- |
006 1件: 6 💬 |
190 |
Ambroxol |
Ambroxol |
1件: D07442 D07442 💬 |
- |
- |
006 2件: 6, 19 💬 |
191 |
Ambroxol hydrochloride |
Ambroxol |
1件: D07442 D07442 💬 |
- |
- |
006 1件: 6 💬 |
192 |
Ammonia |
Ammonia |
1件: D02916 D02916 💬 |
- |
- |
006 4件: 6, 17, 86, 88 💬 |
193 |
Amoxicillin |
Amoxicillin |
3件: D00229 D00229, D02925 D02925, D07452 D07452 💬 |
- |
- |
006 7件: 6, 46, 63, 96, 97, 222, 299 💬 |
194 |
Ampreloxetine |
Ampreloxetine |
1件: D11688 D11688 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6, 17 💬 |
195 |
Ampreloxetine chydrochloride |
Ampreloxetine |
1件: D11688 D11688 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6, 17 💬 |
196 |
Ampreloxetine hydrochloride |
Ampreloxetine |
1件: D11688 D11688 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6, 17 💬 |
197 |
Ampyra |
- |
- |
- |
- |
006 2件: 6, 13 💬 |
198 |
Ampyra first, |
- |
- |
- |
- |
006 1件: 6 💬 |
199 |
Anavex2-73 |
- |
- |
- |
- |
006 2件: 6, 156 💬 |
200 |
Anhydrous carbidopa |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
201 |
Anti-parkinson medication |
- |
- |
- |
- |
005 5件: 5, 6, 7, 8, 17 💬 |
202 |
Antiparkinsonian agent(s) |
- |
- |
- |
- |
006 1件: 6 💬 |
203 |
Ap |
- |
- |
- |
- |
002 4件: 2, 6, 13, 299 💬 |
204 |
Ap-cd/ld |
- |
- |
- |
- |
006 1件: 6 💬 |
205 |
Ap09004 |
- |
- |
- |
- |
006 1件: 6 💬 |
206 |
Apl-130277 |
- |
- |
- |
- |
006 1件: 6 💬 |
207 |
Aplindore |
Aplindore |
- |
- |
- |
006 1件: 6 💬 |
208 |
Aplindore mr tablets |
Aplindore |
- |
- |
- |
006 1件: 6 💬 |
209 |
Apo-go |
- |
- |
- |
- |
006 1件: 6 💬 |
210 |
Apo-go® |
- |
- |
- |
- |
006 1件: 6 💬 |
211 |
Apokinon |
- |
- |
- |
- |
006 1件: 6 💬 |
212 |
Apokyn |
- |
- |
- |
- |
006 1件: 6 💬 |
213 |
Apomor |
- |
- |
- |
- |
006 1件: 6 💬 |
214 |
Apomorp |
- |
- |
- |
- |
006 1件: 6 💬 |
215 |
Apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
216 |
Apomorphine 0.25% (2.5mg/ml) |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
217 |
Apomorphine hcl injection |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
218 |
Apomorphine hydrochloride |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
219 |
Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
220 |
Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
221 |
Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
222 |
Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
223 |
Apomorphine hydrochloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
224 |
Apomorphine hydrocloride |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
225 |
Apomorphine hydrocloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
226 |
Apomorphine infusion |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
227 |
Apomorphine nasal powder |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
228 |
Aporon |
- |
- |
- |
- |
006 1件: 6 💬 |
229 |
Aqw051 |
- |
- |
- |
- |
006 1件: 6 💬 |
230 |
Aricept |
- |
- |
- |
- |
006 4件: 6, 13, 78, 124 💬 |
231 |
Aricept 5 mg-filmtabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
232 |
Aricept 5mg-filmtabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
233 |
Aripiprazole |
Aripiprazole |
1件: D01164 D01164 💬 |
DRD2 4件: DRD2, DRD3, HTR1A, HTR2A 💬 |
Alcoholism 12件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
006 2件: 6, 206 💬 |
234 |
Armodafinil |
Armodafinil |
1件: D03215 D03215 💬 |
SLC6A3 1件: SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 3件: 6, 13, 84 💬 |
235 |
Artane |
- |
- |
- |
- |
006 1件: 6 💬 |
236 |
As2 |
- |
- |
- |
- |
006 1件: 6 💬 |
237 |
Asyn mab |
- |
- |
- |
- |
006 1件: 6 💬 |
238 |
At 10 |
- |
- |
- |
- |
006 1件: 6 💬 |
239 |
Atm fog in pd |
- |
- |
- |
- |
006 1件: 6 💬 |
240 |
Atomoxetine |
Atomoxetine |
2件: D02574 D02574, D07473 D07473 💬 |
SLC6A2 1件: SLC6A2 💬 |
Synaptic vesicle cycle 1件: Synaptic vesicle cycle |
006 3件: 6, 8, 13 💬 |
241 |
Atypical antipsychotics |
- |
- |
- |
- |
006 1件: 6 💬 |
242 |
Autologous mesenchymal stem cells |
- |
- |
- |
- |
002 5件: 2, 6, 13, 17, 46 💬 |
243 |
Av-101 |
AV-101 |
- |
- |
- |
006 1件: 6 💬 |
244 |
Avalox |
- |
- |
- |
- |
006 1件: 6 💬 |
245 |
Avalox - 400 mg compresse rivestite con film 5 compresse in blister pp/al |
- |
- |
- |
- |
006 1件: 6 💬 |
246 |
Ave8112 |
- |
- |
- |
- |
006 1件: 6 💬 |
247 |
Avp-923 |
- |
- |
- |
- |
002 3件: 2, 6, 13 💬 |
248 |
Avp-923-45 |
- |
- |
- |
- |
006 1件: 6 💬 |
249 |
Azathioprine |
Azathioprine |
2件: D00238 D00238, D03033 D03033 💬 |
- |
- |
006 20件: 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 94, 95, 96, 97, 162 💬 |
250 |
Azd3241 |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
251 |
Azd3241 300 mg bid |
- |
- |
- |
- |
006 1件: 6 💬 |
252 |
Azd3241 600 mg bid |
- |
- |
- |
- |
006 1件: 6 💬 |
253 |
Azd3241 alternative titration scheme with formulation 1 or 2 |
- |
- |
- |
- |
006 1件: 6 💬 |
254 |
Azd3241 er formulation 1 |
- |
- |
- |
- |
006 1件: 6 💬 |
255 |
Azd3241 extended release tablets 100 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
256 |
Azd3241 extended release tablets 25 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
257 |
Azilect |
- |
- |
- |
- |
002 4件: 2, 5, 6, 17 💬 |
258 |
Azilect 1 mg comprimidos |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
259 |
Azilect 1mg |
- |
- |
- |
- |
006 1件: 6 💬 |
260 |
Azilect® |
- |
- |
- |
- |
006 1件: 6 💬 |
261 |
B-cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
262 |
B6, b12, l-methylfolate |
Levomefolic acid |
1件: D09353 D09353 💬 |
- |
- |
006 1件: 6 💬 |
263 |
Balance |
Isoxaflutole |
- |
- |
- |
005 9件: 5, 6, 13, 46, 81, 113, 122, 149, 299 💬 |
264 |
Band |
- |
- |
- |
- |
006 2件: 6, 97 💬 |
265 |
Bavisant |
Bavisant |
1件: D09870 D09870 💬 |
HRH3 1件: HRH3 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
266 |
Bavisant dihydrochloride monohydrate |
Bavisant |
1件: D09870 D09870 💬 |
HRH3 1件: HRH3 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
267 |
Bavisant hydrochloride monohydrate |
Bavisant |
1件: D09870 D09870 💬 |
HRH3 1件: HRH3 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
268 |
Beam |
Tricyclazole |
- |
- |
- |
006 2件: 6, 51 💬 |
269 |
Bee venom |
- |
- |
- |
- |
006 1件: 6 💬 |
270 |
Behavioral: assessment of cognition |
- |
- |
- |
- |
006 1件: 6 💬 |
271 |
Behavioral: assessment of depression |
- |
- |
- |
- |
006 1件: 6 💬 |
272 |
Behavioral: assessment of motor and non-motors symptoms of pd evaluation of hyper- and hypodopaminergic behaviors |
- |
- |
- |
- |
006 1件: 6 💬 |
273 |
Behavioral: assessment of quality of life |
- |
- |
- |
- |
006 1件: 6 💬 |
274 |
Behavioral: assessment of severity of icd (impulse control disorders) |
- |
- |
- |
- |
006 1件: 6 💬 |
275 |
Behavioral: assessment of severity of parkinson disease |
- |
- |
- |
- |
006 1件: 6 💬 |
276 |
Behavioral: attention control |
- |
- |
- |
- |
006 1件: 6 💬 |
277 |
Behavioral: augmented reality multi-modal training |
- |
- |
- |
- |
006 1件: 6 💬 |
278 |
Behavioral: balance & strengthening exercises |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
279 |
Behavioral: balance training |
Isoxaflutole |
- |
- |
- |
006 2件: 6, 13 💬 |
280 |
Behavioral: bci-fit active querying |
- |
- |
- |
- |
002 3件: 2, 6, 17 💬 |
281 |
Behavioral: bci-fit adaptive signal modeling |
- |
- |
- |
- |
002 3件: 2, 6, 17 💬 |
282 |
Behavioral: bci-fit language modeling |
- |
- |
- |
- |
002 3件: 2, 6, 17 💬 |
283 |
Behavioral: bci-fit multi-modal access |
- |
- |
- |
- |
002 3件: 2, 6, 17 💬 |
284 |
Behavioral: brisk walking and balance training |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
285 |
Behavioral: building better caregivers workshop |
- |
- |
- |
- |
006 1件: 6 💬 |
286 |
Behavioral: cbt and sleep hygiene |
- |
- |
- |
- |
006 1件: 6 💬 |
287 |
Behavioral: co-op treatment protocol |
- |
- |
- |
- |
006 1件: 6 💬 |
288 |
Behavioral: cognitive and behavioral experimental tasks |
- |
- |
- |
- |
006 2件: 6, 127 💬 |
289 |
Behavioral: combined balance and brisk walking training |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
290 |
Behavioral: conservative measures for orthostatic hypotension |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
291 |
Behavioral: dexterity |
- |
- |
- |
- |
006 1件: 6 💬 |
292 |
Behavioral: dual task |
- |
- |
- |
- |
006 1件: 6 💬 |
293 |
Behavioral: ecocapture |
- |
- |
- |
- |
006 2件: 6, 127 💬 |
294 |
Behavioral: emotion assessment |
- |
- |
- |
- |
006 1件: 6 💬 |
295 |
Behavioral: exercise |
- |
- |
- |
- |
006 3件: 6, 265, 299 💬 |
296 |
Behavioral: exercise only |
- |
- |
- |
- |
006 1件: 6 💬 |
297 |
Behavioral: exercise+multi-modal sensory feedback (mmsf) |
- |
- |
- |
- |
006 1件: 6 💬 |
298 |
Behavioral: flexibility and strengthening exercise |
- |
- |
- |
- |
006 1件: 6 💬 |
299 |
Behavioral: gait and balance |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
300 |
Behavioral: gait and balance training program |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
301 |
Behavioral: healthy age-matched controls |
- |
- |
- |
- |
006 1件: 6 💬 |
302 |
Behavioral: icm_apathy_tasks |
- |
- |
- |
- |
006 2件: 6, 127 💬 |
303 |
Behavioral: levodopa or acupuncture |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
304 |
Behavioral: low-impact exercise control |
- |
- |
- |
- |
006 1件: 6 💬 |
305 |
Behavioral: memory |
- |
- |
- |
- |
006 1件: 6 💬 |
306 |
Behavioral: participant open-response writing |
- |
- |
- |
- |
006 1件: 6 💬 |
307 |
Behavioral: participant self-assessment surveys |
- |
- |
- |
- |
006 1件: 6 💬 |
308 |
Behavioral: pat sessions |
- |
- |
- |
- |
006 1件: 6 💬 |
309 |
Behavioral: pelvic floor muscle exercise-based behavioral therapy |
- |
- |
- |
- |
006 1件: 6 💬 |
310 |
Behavioral: phonation |
- |
- |
- |
- |
006 1件: 6 💬 |
311 |
Behavioral: physical exam and updrs part iii assessment |
- |
- |
- |
- |
006 1件: 6 💬 |
312 |
Behavioral: physical therapy |
- |
- |
- |
- |
006 1件: 6 💬 |
313 |
Behavioral: resistance training |
- |
- |
- |
- |
006 1件: 6 💬 |
314 |
Behavioral: rest |
- |
- |
- |
- |
006 1件: 6 💬 |
315 |
Behavioral: role of dopamine |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
316 |
Behavioral: single task |
- |
- |
- |
- |
006 1件: 6 💬 |
317 |
Behavioral: strength training |
- |
- |
- |
- |
006 1件: 6 💬 |
318 |
Behavioral: stretching |
- |
- |
- |
- |
006 1件: 6 💬 |
319 |
Behavioral: tai chi |
- |
- |
- |
- |
006 1件: 6 💬 |
320 |
Behavioral: traditional multi-modal training |
- |
- |
- |
- |
006 1件: 6 💬 |
321 |
Behavioral: upper limb exercise |
- |
- |
- |
- |
006 1件: 6 💬 |
322 |
Ben-2001 |
- |
- |
- |
- |
006 1件: 6 💬 |
323 |
Benserazide |
Benserazide |
1件: D03082 D03082 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
324 |
Benserazide hydrochloride |
Benserazide |
1件: D03082 D03082 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
325 |
Benzofuran |
Benzofuran |
- |
- |
- |
006 1件: 6 💬 |
326 |
Berachin |
- |
- |
- |
- |
006 1件: 6 💬 |
327 |
Best medical treatment |
- |
- |
- |
- |
006 1件: 6 💬 |
328 |
Best médical treatment |
- |
- |
- |
- |
006 1件: 6 💬 |
329 |
Betaquik mct supplement |
- |
- |
- |
- |
006 1件: 6 💬 |
330 |
Better |
- |
- |
- |
- |
006 1件: 6 💬 |
331 |
Bf 2.649 |
- |
- |
- |
- |
006 1件: 6 💬 |
332 |
Bf 2.649 10 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
333 |
Bf 2.649 20 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
334 |
Bf 2.649 40 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
335 |
Bf 2.649 5 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
336 |
Bf2.649 |
- |
- |
- |
- |
006 1件: 6 💬 |
337 |
Bf2.649 (pitolisant) |
Pitolisant |
1件: D10749 D10749 💬 |
HRH3 1件: HRH3 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
338 |
Bi-sifrol® |
- |
- |
- |
- |
006 1件: 6 💬 |
339 |
Bia |
BIA |
- |
- |
- |
006 2件: 6, 86 💬 |
340 |
Bia 3-202 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
341 |
Bia 3-202 (200 mg) |
BIA |
- |
- |
- |
006 1件: 6 💬 |
342 |
Bia 6-512 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
343 |
Bia 6-512 100 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
344 |
Bia 6-512 100 mg dose |
BIA |
- |
- |
- |
006 1件: 6 💬 |
345 |
Bia 6-512 200 mg dose |
BIA |
- |
- |
- |
006 1件: 6 💬 |
346 |
Bia 6-512 25 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
347 |
Bia 6-512 25 mg dose |
BIA |
- |
- |
- |
006 1件: 6 💬 |
348 |
Bia 6-512 400 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
349 |
Bia 6-512 50 mg dose |
BIA |
- |
- |
- |
006 1件: 6 💬 |
350 |
Bia 9-1067 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
351 |
Bia 9-1067 (test) |
BIA |
- |
- |
- |
006 1件: 6 💬 |
352 |
Bia 9-1067 15 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
353 |
Bia 9-1067 25 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
354 |
Bia 9-1067 30 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
355 |
Bia 9-1067 5 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
356 |
Bia 9-1067 micronized |
BIA |
- |
- |
- |
006 1件: 6 💬 |
357 |
Bia 9-1067 non-micronized |
BIA |
- |
- |
- |
006 1件: 6 💬 |
358 |
Biib014 |
- |
- |
- |
- |
006 1件: 6 💬 |
359 |
Biib054 |
- |
- |
- |
- |
006 1件: 6 💬 |
360 |
Biib094 |
- |
- |
- |
- |
006 1件: 6 💬 |
361 |
Bisphosphonates |
- |
- |
- |
- |
006 2件: 6, 274 💬 |
362 |
Bone marrow derived mesenchymal stem cells |
- |
- |
- |
- |
006 2件: 6, 60 💬 |
363 |
Bont-a |
- |
- |
- |
- |
006 1件: 6 💬 |
364 |
Botox |
- |
- |
- |
- |
002 6件: 2, 6, 13, 51, 149, 226 💬 |
365 |
Botulinum toxin |
- |
- |
- |
- |
006 3件: 6, 13, 149 💬 |
366 |
Botulinum toxin type a |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
002 10件: 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 💬 |
367 |
Botulinum toxin type b |
Botulinum Toxin Type B |
1件: D02735 D02735 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
002 3件: 2, 6, 51 💬 |
368 |
Botulinum toxin type b (myobloc) |
Botulinum Toxin Type B |
1件: D02735 D02735 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
002 2件: 2, 6 💬 |
369 |
Botulinum toxin: xeomin |
- |
- |
- |
- |
006 1件: 6 💬 |
370 |
Bromocriptine |
Bromocriptine |
2件: D00780 D00780, D03165 D03165 💬 |
DRD2 2件: DRD2, PRL 💬 |
Alcoholism 12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
006 2件: 6, 74 💬 |
371 |
Bromocriptine and other dopamine agonists |
Bromocriptine |
4件: D00633 D00633, D00780 D00780, D03165 D03165, D07870 D07870 💬 |
DRD1 6件: DRD1, DRD2, DRD3, DRD4, DRD5, PRL 💬 |
Alcoholism 15件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
372 |
Btrx-246040 |
BTRX-246040 |
- |
- |
- |
006 1件: 6 💬 |
373 |
Btx-a |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
006 1件: 6 💬 |
374 |
Bumetanide |
Bumetanide |
1件: D00247 D00247 💬 |
SLC12A2 1件: SLC12A2 💬 |
Pancreatic secretion 3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection |
006 2件: 6, 158 💬 |
375 |
Bumetanide white, oblong, scored tablet |
Bumetanide |
1件: D00247 D00247 💬 |
SLC12A2 1件: SLC12A2 💬 |
Pancreatic secretion 3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection |
006 1件: 6 💬 |
376 |
Bupleurum+ginkgo |
Ginkgo biloba |
- |
- |
- |
006 1件: 6 💬 |
377 |
Buspirone |
Buspirone |
2件: D00702 D00702, D07593 D07593 💬 |
DRD2 2件: DRD2, HTR1A 💬 |
Alcoholism 10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
006 2件: 6, 51 💬 |
378 |
Buspirone hydrochloride |
Buspirone |
2件: D00702 D00702, D07593 D07593 💬 |
DRD2 2件: DRD2, HTR1A 💬 |
Alcoholism 10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
379 |
Butylphthalide |
Butylphthalide |
- |
- |
- |
002 4件: 2, 6, 18, 22 💬 |
380 |
Bydureon |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
381 |
Bydureon 2 mg powder and solvent for prolonged-release suspension |
- |
- |
- |
- |
006 1件: 6 💬 |
382 |
Byetta |
- |
- |
- |
- |
006 2件: 6, 193 💬 |
383 |
Byetta 5 micrograms |
- |
- |
- |
- |
006 1件: 6 💬 |
384 |
Cabaser |
- |
- |
- |
- |
006 1件: 6 💬 |
385 |
Cabaseril |
- |
- |
- |
- |
006 1件: 6 💬 |
386 |
Cabaseril, 1,0 mg tablette |
- |
- |
- |
- |
006 1件: 6 💬 |
387 |
Cabaseril, 2,0 mg tablette |
- |
- |
- |
- |
006 1件: 6 💬 |
388 |
Cabergolina |
Cabergoline |
1件: D00987 D00987 💬 |
DRD2 2件: DRD2, PRL 💬 |
Alcoholism 12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
389 |
Cabergoline |
Cabergoline |
1件: D00987 D00987 💬 |
DRD2 2件: DRD2, PRL 💬 |
Alcoholism 12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
006 3件: 6, 74, 75 💬 |
390 |
Caffeine |
Caffeine |
2件: D00528 D00528, D01453 D01453 💬 |
ADORA1 11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 |
Alcoholism 22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
002 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265 💬 |
391 |
Caffeine 100-200 mg bid |
Caffeine |
2件: D00528 D00528, D01453 D01453 💬 |
ADORA1 11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 |
Alcoholism 22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
392 |
Caffeine alkaloid |
Caffeine |
2件: D00528 D00528, D01453 D01453 💬 |
ADORA1 11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 |
Alcoholism 22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
393 |
Calcium |
Calcium |
- |
- |
- |
006 27件: 6, 13, 19, 46, 49, 51, 53, 56, 68, 75, 79, 84, 93, 94, 95, 96, 97, 186, 214, 215, 222, 224, 235, 265, 274, 298, 299 💬 |
394 |
Cannabidiol |
Cannabidiol |
1件: D10915 D10915 💬 |
CNR1 2件: CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
006 17件: 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 226, 271 💬 |
395 |
Cannabidiol (cbd) |
Cannabidiol |
1件: D10915 D10915 💬 |
CNR1 2件: CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
006 6件: 6, 140, 144, 145, 156, 158 💬 |
396 |
Cannabis |
Medical Cannabis |
- |
- |
- |
002 8件: 2, 6, 13, 46, 90, 96, 97, 271 💬 |
397 |
Cannabis oil |
Medical Cannabis |
- |
- |
- |
006 1件: 6 💬 |
398 |
Cannabis, medical |
Medical Cannabis |
- |
- |
- |
002 5件: 2, 6, 13, 96, 97 💬 |
399 |
Capsaicin |
Capsaicin |
1件: D00250 D00250 💬 |
TRPV1 1件: TRPV1 💬 |
Inflammatory mediator regulation of TRP channels 2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
002 5件: 2, 6, 19, 86, 226 💬 |
400 |
Capsaicin vapor |
Capsaicin |
1件: D00250 D00250 💬 |
TRPV1 1件: TRPV1 💬 |
Inflammatory mediator regulation of TRP channels 2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
401 |
Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
402 |
Capture |
Bifenthrin |
- |
- |
- |
006 2件: 6, 46 💬 |
403 |
Carbidopa |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
002 9件: 2, 4, 6, 13, 17, 90, 140, 164, 201 💬 |
404 |
Carbidopa (fu) |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
405 |
Carbidopa 20 mg |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
406 |
Carbidopa 200mg oral dose |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 2件: 6, 17 💬 |
407 |
Carbidopa 27.5 mg |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
408 |
Carbidopa 65 mg capsule |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
409 |
Carbidopa and levodopa 25mg/100mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
410 |
Carbidopa and levodopa tablets, usp |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
411 |
Carbidopa anidra |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
412 |
Carbidopa fu |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
413 |
Carbidopa inn |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
414 |
Carbidopa levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
415 |
Carbidopa monohydrate |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
416 |
Carbidopa, levodopa, entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
417 |
Carbidopa- levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
418 |
Carbidopa-4'-monophosphate |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
419 |
Carbidopa-levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
002 3件: 2, 4, 6 💬 |
420 |
Carbidopa-levodopa 25 mg-100 mg oral tablet |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
421 |
Carbidopa/l-dopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
422 |
Carbidopa/l-dopa/entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
423 |
Carbidopa/levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
424 |
Carbidopa/levodopa, immediate release |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
425 |
Carbidopa/levodopa/entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
426 |
Carbidopamonohydraat |
- |
- |
- |
- |
006 1件: 6 💬 |
427 |
Carbodopa levadopa |
- |
- |
- |
- |
006 1件: 6 💬 |
428 |
Carbodopa/levadopa |
- |
- |
- |
- |
006 1件: 6 💬 |
429 |
Carbon |
Activated charcoal |
1件: D03251 D03251 💬 |
- |
- |
006 9件: 6, 46, 50, 51, 85, 86, 96, 97, 298 💬 |
430 |
Carnosine |
Carnosine |
- |
- |
- |
006 2件: 6, 13 💬 |
431 |
Carnosine supplementation |
Carnosine |
- |
- |
- |
006 1件: 6 💬 |
432 |
Carvedilol |
Carvedilol |
2件: D00255 D00255, D03415 D03415 💬 |
ADRA1A 5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 💬 |
AMPK signaling pathway 12件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 5件: 6, 57, 86, 113, 210 💬 |
433 |
Catapres ampoules |
- |
- |
- |
- |
006 1件: 6 💬 |
434 |
Catapressan |
- |
- |
- |
- |
006 1件: 6 💬 |
435 |
Cbd |
- |
- |
- |
- |
002 11件: 2, 6, 8, 13, 46, 140, 144, 145, 156, 158, 206 💬 |
436 |
Cd |
- |
- |
- |
- |
006 6件: 6, 46, 51, 96, 97, 265 💬 |
437 |
Cd-ld cr |
- |
- |
- |
- |
006 1件: 6 💬 |
438 |
Cd-ld ir |
- |
- |
- |
- |
006 1件: 6 💬 |
439 |
Cdnf |
- |
- |
- |
- |
006 1件: 6 💬 |
440 |
Ceftriaxone |
Ceftriaxone |
2件: D00924 D00924, D07659 D07659 💬 |
- |
- |
002 3件: 2, 6, 97 💬 |
441 |
Cep-1347 |
CEP-1347 |
- |
- |
- |
006 1件: 6 💬 |
442 |
Cep-1347 10mg |
CEP-1347 |
- |
- |
- |
006 1件: 6 💬 |
443 |
Cep-1347 50mg |
CEP-1347 |
- |
- |
- |
006 1件: 6 💬 |
444 |
Cep1347 |
- |
- |
- |
- |
006 1件: 6 💬 |
445 |
Cep1347 25mg |
- |
- |
- |
- |
006 1件: 6 💬 |
446 |
Cere-120 |
- |
- |
- |
- |
006 1件: 6 💬 |
447 |
Cere-120 (adeno-associated virus serotype 2 [aav2]-neurturin [ntn]) |
- |
- |
- |
- |
006 1件: 6 💬 |
448 |
Cere-120: adeno-associated virus delivery of neurturin |
- |
- |
- |
- |
006 1件: 6 💬 |
449 |
Cerebral dopamine neurotrophic factor |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
450 |
Ceretec |
- |
- |
- |
- |
006 1件: 6 💬 |
451 |
Ceretec (tm) estabilizado |
- |
- |
- |
- |
006 1件: 6 💬 |
452 |
Champix |
- |
- |
- |
- |
006 1件: 6 💬 |
453 |
Chloride |
Chloride ion |
- |
- |
- |
006 25件: 6, 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 97, 127, 168, 171, 193, 227, 228, 271, 288, 296, 297, 299 💬 |
454 |
Chocolate |
Cocoa |
- |
- |
- |
006 1件: 6 💬 |
455 |
Cipralex |
- |
- |
- |
- |
006 1件: 6 💬 |
456 |
Circadin |
- |
- |
- |
- |
006 3件: 6, 13, 90 💬 |
457 |
Circadin® |
- |
- |
- |
- |
006 1件: 6 💬 |
458 |
Citalopram |
Citalopram |
2件: D00822 D00822, D07704 D07704 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 6件: 6, 8, 13, 18, 46, 127 💬 |
459 |
Citalopram 20mg |
Citalopram |
2件: D00822 D00822, D07704 D07704 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 1件: 6 💬 |
460 |
Cjh1 (clr4001) |
- |
- |
- |
- |
006 1件: 6 💬 |
461 |
Clarithromycin |
Clarithromycin |
1件: D00276 D00276 💬 |
- |
- |
006 8件: 6, 63, 84, 96, 97, 222, 228, 299 💬 |
462 |
Clarithromycin (not used as of 4/2020) |
Clarithromycin |
1件: D00276 D00276 💬 |
- |
- |
006 1件: 6 💬 |
463 |
Clarium 50 mg retardtabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
464 |
Clartihromycin, amoxicillin, and omeprazole |
Amoxicillin |
7件: D00229 D00229, D00455 D00455, D01207 D01207, D02925 D02925, D05259 D05259, D05261 D05261, D07452 D07452 💬 |
ATP4A 2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
006 1件: 6 💬 |
465 |
Cle |
- |
- |
- |
- |
006 1件: 6 💬 |
466 |
Clenbuterol |
Clenbuterol |
1件: D07713 D07713 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
001 4件: 1, 2, 6, 256 💬 |
467 |
Clenbuterol hcl |
Clenbuterol |
1件: D07713 D07713 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
468 |
Clenbuterol hydrochloride |
Clenbuterol |
1件: D07713 D07713 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
469 |
Clonazepam |
Clonazepam |
1件: D00280 D00280 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 1件: 6 💬 |
470 |
Clonidine |
Clonidine |
2件: D00281 D00281, D00604 D00604 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 2件: 6, 78 💬 |
471 |
Clonidine hydrochloride |
Clonidine |
2件: D00281 D00281, D00604 D00604 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 2件: 6, 78 💬 |
472 |
Clozapine |
Clozapine |
1件: D00283 D00283 💬 |
ADRA2A 11件: ADRA2A, ADRA2B, ADRA2C, DRD4, HTR2A, HTR2C, HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 |
Calcium signaling pathway 8件: Calcium signaling pathway, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
473 |
Co |
- |
- |
- |
- |
006 5件: 6, 13, 53, 70, 85 💬 |
474 |
Cocoa |
Cocoa |
- |
- |
- |
006 1件: 6 💬 |
475 |
Coenzyme q10 |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
002 12件: 2, 5, 6, 8, 10, 18, 46, 57, 113, 193, 214, 215 💬 |
476 |
Coenzyme q10 nanodispersion (nanoquinone) |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
006 1件: 6 💬 |
477 |
Coenzyme q10 with vitamin e |
Ubidecarenone |
2件: D01065 D01065, D02331 D02331 💬 |
- |
- |
006 1件: 6 💬 |
478 |
Cofactor |
- |
- |
- |
- |
006 3件: 6, 265, 288 💬 |
479 |
Cogane |
- |
- |
- |
- |
006 1件: 6 💬 |
480 |
Cogane™ (pym50028) |
- |
- |
- |
- |
006 1件: 6 💬 |
481 |
Cohort 1:nilotinib oral capsules (150mg or 300mg) |
Nilotinib |
1件: D08953 D08953 💬 |
ABL1 4件: ABL1, KIT, PDGFRA, PDGFRB 💬 |
Acute myeloid leukemia 32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
006 1件: 6 💬 |
482 |
Cohort 2: nilotinib oral capsules (dose to be determined from cohort 1) |
Nilotinib |
1件: D08953 D08953 💬 |
ABL1 4件: ABL1, KIT, PDGFRA, PDGFRB 💬 |
Acute myeloid leukemia 32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
006 1件: 6 💬 |
483 |
Combination injection of epo and g-csf |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
006 1件: 6 💬 |
484 |
Combination product: l-dopa 140 mg |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
485 |
Combination product: l-dopa 35 mg |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
486 |
Combination product: l-dopa 70mg |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
487 |
Combination product: l-dopa 70mg/carbidopa 7mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
488 |
Combination product: nd0612 solution for sc infusion |
- |
- |
- |
- |
006 1件: 6 💬 |
489 |
Comparator: carbidopa |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
490 |
Comparator: levodopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
491 |
Comtan |
- |
- |
- |
- |
006 1件: 6 💬 |
492 |
Comtan 200* 60 cpr 200 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
493 |
Comtan® |
- |
- |
- |
- |
006 1件: 6 💬 |
494 |
Comtanâ® |
- |
- |
- |
- |
006 1件: 6 💬 |
495 |
Comtess |
- |
- |
- |
- |
006 1件: 6 💬 |
496 |
Comtess® |
- |
- |
- |
- |
006 1件: 6 💬 |
497 |
Continuous apomorphine infusion |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
498 |
Continuous intrajejunal infusion of levodopa-carbidopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
499 |
Continuous release dopamine agonists |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
500 |
Continuous subcutaneous lisuride infusion |
Lisuride |
2件: D01462 D01462, D08132 D08132 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
501 |
Control |
- |
- |
- |
- |
006 4件: 6, 46, 168, 299 💬 |
502 |
Controlled-release levodopa / carbidopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
503 |
Coq10 |
- |
- |
- |
- |
005 3件: 5, 6, 8 💬 |
504 |
Cord blood therapy |
Umbilical Cord Blood Hematopoietic Stem Cells |
- |
- |
- |
002 2件: 2, 6 💬 |
505 |
Cortef |
- |
- |
- |
- |
006 3件: 6, 81, 83 💬 |
506 |
Cp |
- |
- |
- |
- |
006 6件: 6, 46, 96, 97, 107, 271 💬 |
507 |
Creatine |
Creatine |
- |
- |
- |
001 12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 💬 |
508 |
Cst-103 |
- |
- |
- |
- |
006 1件: 6 💬 |
509 |
Cst-139 |
- |
- |
- |
- |
006 1件: 6 💬 |
510 |
Cu(ii)atsm |
- |
- |
- |
- |
002 2件: 2, 6 💬 |
511 |
Cvd00118-e |
- |
- |
- |
- |
006 1件: 6 💬 |
512 |
Cvl-751 |
- |
- |
- |
- |
006 1件: 6 💬 |
513 |
Cvn424 high dose |
- |
- |
- |
- |
006 1件: 6 💬 |
514 |
Cvn424 low dose |
- |
- |
- |
- |
006 1件: 6 💬 |
515 |
Cvt-301 |
- |
- |
- |
- |
006 1件: 6 💬 |
516 |
Cvt-301 (dose level 1) |
- |
- |
- |
- |
006 1件: 6 💬 |
517 |
Cvt-301 (dose level 2) |
- |
- |
- |
- |
006 1件: 6 💬 |
518 |
Cvt-301 35mg |
- |
- |
- |
- |
006 1件: 6 💬 |
519 |
Cvt-301 50mg |
- |
- |
- |
- |
006 1件: 6 💬 |
520 |
Cvt-301 high dose |
- |
- |
- |
- |
006 1件: 6 💬 |
521 |
Cvt-301 low dose |
- |
- |
- |
- |
006 1件: 6 💬 |
522 |
Cvt-301, lip |
- |
- |
- |
- |
006 1件: 6 💬 |
523 |
Cvxl-0107 |
- |
- |
- |
- |
006 1件: 6 💬 |
524 |
Cx-8998 |
- |
- |
- |
- |
006 1件: 6 💬 |
525 |
Cyberknife |
- |
- |
- |
- |
006 1件: 6 💬 |
526 |
Cymbalta |
- |
- |
- |
- |
006 3件: 6, 13, 49 💬 |
527 |
Cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
006 11件: 6, 13, 19, 34, 84, 85, 88, 90, 254, 296, 310 💬 |
528 |
Cystoscopic injection of botox into the urinary bladder |
- |
- |
- |
- |
006 1件: 6 💬 |
529 |
D-serine |
D-Serine |
1件: D00016 D00016 💬 |
- |
- |
006 1件: 6 💬 |
530 |
D-serine (~2g/day) |
D-Serine |
1件: D00016 D00016 💬 |
- |
- |
006 1件: 6 💬 |
531 |
Da-9701 |
- |
- |
- |
- |
006 1件: 6 💬 |
532 |
Da-9805 45mg |
- |
- |
- |
- |
006 1件: 6 💬 |
533 |
Da-9805 90mg |
- |
- |
- |
- |
006 1件: 6 💬 |
534 |
Daaoi-p |
- |
- |
- |
- |
006 1件: 6 💬 |
535 |
Dacepton 5 mg/ml |
- |
- |
- |
- |
006 1件: 6 💬 |
536 |
Dacepton 5 mg/ml infuusioneste, liuos |
- |
- |
- |
- |
006 1件: 6 💬 |
537 |
Daily ingestion of lactobacillus plantarum ps128 |
Lactobacillus plantarum |
- |
- |
- |
006 1件: 6 💬 |
538 |
Darifenacin |
Darifenacin |
2件: D01699 D01699, D03654 D03654 💬 |
CHRM3 1件: CHRM3 💬 |
Alzheimer disease 11件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
006 2件: 6, 13 💬 |
539 |
Dark chocolate (85% cocoa) |
Cocoa |
- |
- |
- |
006 1件: 6 💬 |
540 |
Datscan |
- |
- |
- |
- |
002 4件: 2, 5, 6, 17 💬 |
541 |
Datscan 74 mbq/ml solution for injection |
- |
- |
- |
- |
006 1件: 6 💬 |
542 |
Datscan™ |
- |
- |
- |
- |
006 1件: 6 💬 |
543 |
Datscan™ ioflupane (123i) injection |
- |
- |
- |
- |
005 3件: 5, 6, 17 💬 |
544 |
Dc158am |
- |
- |
- |
- |
006 1件: 6 💬 |
545 |
Dci |
- |
- |
- |
- |
006 2件: 6, 299 💬 |
546 |
Dcs |
- |
- |
- |
- |
006 1件: 6 💬 |
547 |
Deanol |
Deanol |
1件: D07777 D07777 💬 |
- |
- |
006 1件: 6 💬 |
548 |
Deanol pyroglutamate |
Deanol |
1件: D07777 D07777 💬 |
- |
- |
006 1件: 6 💬 |
549 |
Debrumyl |
- |
- |
- |
- |
006 1件: 6 💬 |
550 |
Deferiprone |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
002 6件: 2, 6, 18, 120, 122, 233 💬 |
551 |
Deferiprone (ferriprox) |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
552 |
Deferiprone 20mg |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
553 |
Deferiprone 30mg |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
554 |
Deferiprone 600 mg delayed release tablet |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
555 |
Deferiprone dr |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
556 |
Desipramine |
Desipramine |
2件: D00812 D00812, D07791 D07791 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 4件: 6, 17, 120, 156 💬 |
557 |
Desipramine (dmi) |
Desipramine |
2件: D00812 D00812, D07791 D07791 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6, 17 💬 |
558 |
Desmopressin |
Desmopressin |
2件: D00291 D00291, D02235 D02235 💬 |
AVPR2 2件: AVPR2, F8 💬 |
Complement and coagulation cascades 4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
006 5件: 6, 64, 72, 225, 288 💬 |
559 |
Desmopressin acetat |
Desmopressin |
2件: D00291 D00291, D02235 D02235 💬 |
AVPR2 2件: AVPR2, F8 💬 |
Complement and coagulation cascades 4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
006 1件: 6 💬 |
560 |
Desmotabs |
- |
- |
- |
- |
006 1件: 6 💬 |
561 |
Desmotabs® 0,2 mg tabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
562 |
Desmotabs® 0,2mg tabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
563 |
Determination of drug effects through amantadine cessation |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
564 |
Device: abdominal compression |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
565 |
Device: actimyo recording |
- |
- |
- |
- |
006 1件: 6 💬 |
566 |
Device: active tdcs |
- |
- |
- |
- |
006 1件: 6 💬 |
567 |
Device: active tpcs |
- |
- |
- |
- |
006 1件: 6 💬 |
568 |
Device: adaptor: hakko adaptor |
- |
- |
- |
- |
006 1件: 6 💬 |
569 |
Device: aha exergame system |
- |
- |
- |
- |
006 1件: 6 💬 |
570 |
Device: b-stn dbs |
- |
- |
- |
- |
006 1件: 6 💬 |
571 |
Device: balance training |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
572 |
Device: balance training with nintendo wii fit |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
573 |
Device: cadd-legacy ambulatory infusion pump |
- |
- |
- |
- |
006 1件: 6 💬 |
574 |
Device: cadd-legacy® 1400 ambulatory infusion pump |
- |
- |
- |
- |
006 1件: 6 💬 |
575 |
Device: carbon fiber ankle foot orthosis (afo) |
Activated charcoal |
1件: D03251 D03251 💬 |
- |
- |
006 1件: 6 💬 |
576 |
Device: clonidine (catapressan) |
Clonidine |
2件: D00281 D00281, D00604 D00604 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
577 |
Device: deep brain stimulation |
- |
- |
- |
- |
005 5件: 5, 6, 7, 8, 17 💬 |
578 |
Device: functional magnetic resonance imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
579 |
Device: infusion pump: cadd-legacy® 1400 pump |
- |
- |
- |
- |
006 1件: 6 💬 |
580 |
Device: inspiratory muscle training |
- |
- |
- |
- |
006 1件: 6 💬 |
581 |
Device: j-tube |
- |
- |
- |
- |
006 1件: 6 💬 |
582 |
Device: jejunal extension tube |
- |
- |
- |
- |
006 1件: 6 💬 |
583 |
Device: jejunal extension tube (j-tube) |
- |
- |
- |
- |
006 1件: 6 💬 |
584 |
Device: kinetra and soletra (neurostimulator, medtronic) |
- |
- |
- |
- |
006 1件: 6 💬 |
585 |
Device: light box ( litebook company) |
- |
- |
- |
- |
006 1件: 6 💬 |
586 |
Device: light box (litebook company) |
- |
- |
- |
- |
006 1件: 6 💬 |
587 |
Device: magnetic resonance imaging |
- |
- |
- |
- |
006 5件: 6, 13, 22, 34, 299 💬 |
588 |
Device: massage with a spiky ball |
- |
- |
- |
- |
006 1件: 6 💬 |
589 |
Device: ms band 2 |
- |
- |
- |
- |
006 1件: 6 💬 |
590 |
Device: nebulizer |
- |
- |
- |
- |
006 1件: 6 💬 |
591 |
Device: nj-tube: silicon ed tube |
Silicon |
- |
- |
- |
006 1件: 6 💬 |
592 |
Device: oct - tce |
- |
- |
- |
- |
006 1件: 6 💬 |
593 |
Device: peg tube |
- |
- |
- |
- |
006 1件: 6 💬 |
594 |
Device: percutaneous endoscopic gastrostomy tube |
- |
- |
- |
- |
006 1件: 6 💬 |
595 |
Device: percutaneous endoscopic gastrostomy tube (peg tube) |
- |
- |
- |
- |
006 1件: 6 💬 |
596 |
Device: renishaw drug delivery system |
- |
- |
- |
- |
006 1件: 6 💬 |
597 |
Device: resistive respiratory loads |
- |
- |
- |
- |
006 1件: 6 💬 |
598 |
Device: sham compression |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
599 |
Device: sham tdcs |
- |
- |
- |
- |
006 1件: 6 💬 |
600 |
Device: sham tpcs |
- |
- |
- |
- |
006 1件: 6 💬 |
601 |
Device: spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
602 |
Device: spoton balance glasses |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
603 |
Device: stimulator off |
- |
- |
- |
- |
006 1件: 6 💬 |
604 |
Device: stimulator on |
- |
- |
- |
- |
006 1件: 6 💬 |
605 |
Dexdor |
- |
- |
- |
- |
002 4件: 2, 4, 6, 70 💬 |
606 |
Dexmedetomidina |
Dexmedetomidine |
2件: D00514 D00514, D01205 D01205 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
607 |
Dexmedetomidine |
Dexmedetomidine |
2件: D00514 D00514, D01205 D01205 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
002 12件: 2, 4, 6, 21, 34, 46, 70, 113, 212, 215, 226, 280 💬 |
608 |
Dexmedetomidine hydrochloride infusion |
Dexmedetomidine |
2件: D00514 D00514, D01205 D01205 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
609 |
Dextromethorphan |
Dextromethorphan |
3件: D00848 D00848, D03742 D03742, D03744 D03744 💬 |
GRIN1 6件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SIGMAR1 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
002 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 💬 |
610 |
Dha |
- |
- |
- |
- |
006 8件: 6, 46, 48, 49, 94, 113, 299, 301 💬 |
611 |
Diagnostic test: [18f]-ro6958948 |
- |
- |
- |
- |
005 5件: 5, 6, 7, 17, 127 💬 |
612 |
Diagnostic test: auto-assessment manikins (sam) |
- |
- |
- |
- |
006 1件: 6 💬 |
613 |
Diagnostic test: barcelona test (bt) |
- |
- |
- |
- |
006 1件: 6 💬 |
614 |
Diagnostic test: beam test to predict falls |
Tricyclazole |
- |
- |
- |
006 1件: 6 💬 |
615 |
Diagnostic test: beck depression inventory-ii (bdi-ii) |
- |
- |
- |
- |
006 1件: 6 💬 |
616 |
Diagnostic test: elecsys (roche) abeta42, ttau and ptau |
- |
- |
- |
- |
005 5件: 5, 6, 7, 17, 127 💬 |
617 |
Diagnostic test: flutemetamol f18 injection |
Flutemetamol |
1件: D10231 D10231 💬 |
- |
- |
005 5件: 5, 6, 7, 17, 127 💬 |
618 |
Diagnostic test: frontal assessment battery (fab) |
- |
- |
- |
- |
006 1件: 6 💬 |
619 |
Diagnostic test: global deterioration scale (gds) |
- |
- |
- |
- |
006 1件: 6 💬 |
620 |
Diagnostic test: lumipulse (fujirebio) abeta42, ttau and ptau |
- |
- |
- |
- |
005 5件: 5, 6, 7, 17, 127 💬 |
621 |
Diagnostic test: measurement of serum level of anti-dementia drug |
- |
- |
- |
- |
006 1件: 6 💬 |
622 |
Diagnostic test: memory alteration test (m@t) |
- |
- |
- |
- |
006 1件: 6 💬 |
623 |
Diagnostic test: mini cognitive examination (mce) |
- |
- |
- |
- |
006 1件: 6 💬 |
624 |
Diagnostic test: neuropsychological assessment |
- |
- |
- |
- |
006 2件: 6, 127 💬 |
625 |
Diagnostic test: positive and negative affect scale (panas) |
- |
- |
- |
- |
006 1件: 6 💬 |
626 |
Diagnostic test: respiratory muscle strength |
- |
- |
- |
- |
006 1件: 6 💬 |
627 |
Diagnostic test: rey-osterrieth complex figure test (rocft) |
- |
- |
- |
- |
006 1件: 6 💬 |
628 |
Diagnostic test: spanish-complutense verbal learning test (tavec) |
- |
- |
- |
- |
006 1件: 6 💬 |
629 |
Diagnostic test: supplementary neuropsychological assessment - parkinson's disease |
- |
- |
- |
- |
006 2件: 6, 127 💬 |
630 |
Different diets |
- |
- |
- |
- |
006 1件: 6 💬 |
631 |
Dihydroergotoxine mesylate |
Ergoloid mesylate |
1件: D02268 D02268 💬 |
ADRA1A 6件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C 💬 |
AMPK signaling pathway 7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
632 |
Dipivefrin |
Dipivefrin |
1件: D02349 D02349 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
633 |
Dipivefrine |
Dipivefrin |
1件: D02349 D02349 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
634 |
Dipraglurant |
Dipraglurant |
- |
- |
- |
006 1件: 6 💬 |
635 |
Ditropan elixir |
- |
- |
- |
- |
006 1件: 6 💬 |
636 |
Dm |
- |
- |
- |
- |
006 2件: 6, 8 💬 |
637 |
Dm-1992 |
- |
- |
- |
- |
006 1件: 6 💬 |
638 |
Dmi |
- |
- |
- |
- |
006 2件: 6, 17 💬 |
639 |
Dnl151 |
- |
- |
- |
- |
006 1件: 6 💬 |
640 |
Dnl201 |
- |
- |
- |
- |
006 1件: 6 💬 |
641 |
Dns-7801 (high dose) |
- |
- |
- |
- |
006 1件: 6 💬 |
642 |
Dns-7801 (low-dose) |
- |
- |
- |
- |
006 1件: 6 💬 |
643 |
Docosahexaenoic acid |
Doconexent |
- |
- |
- |
006 7件: 6, 49, 90, 94, 240, 299, 301 💬 |
644 |
Docosahexaenoic acid (dha) |
Doconexent |
- |
- |
- |
006 3件: 6, 94, 299 💬 |
645 |
Domperidone |
Domperidone |
2件: D01745 D01745, D07868 D07868 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 5件: 6, 13, 17, 51, 230 💬 |
646 |
Domperidone (drug) |
Domperidone |
2件: D01745 D01745, D07868 D07868 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
647 |
Dompéridone |
- |
- |
- |
- |
006 1件: 6 💬 |
648 |
Donepezil |
Donepezil |
2件: D00670 D00670, D07869 D07869 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
005 9件: 5, 6, 13, 46, 78, 124, 127, 156, 206 💬 |
649 |
Donepezil hydrochloride |
Donepezil |
2件: D00670 D00670, D07869 D07869 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 3件: 6, 124, 156 💬 |
650 |
Donepezil sandoz |
Donepezil |
2件: D00670 D00670, D07869 D07869 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
651 |
Dopamine |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 3件: 6, 7, 74 💬 |
652 |
Dopamine agent |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
653 |
Dopamine agonists (pramipexole, ropirinole) |
Dopamine |
4件: D00559 D00559, D00633 D00633, D05575 D05575, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
654 |
Dopaminergic agonist + apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
655 |
Dopaminergic agonists |
- |
- |
- |
- |
006 1件: 6 💬 |
656 |
Dops |
Droxidopa |
1件: D01277 D01277 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 2件: 6, 17 💬 |
657 |
Doxepin |
Doxepin |
2件: D00814 D00814, D07875 D07875 💬 |
HRH1 3件: HRH1, SLC6A2, SLC6A4 💬 |
Calcium signaling pathway 5件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
006 1件: 6 💬 |
658 |
Doxepin and zopiclone |
Doxepin |
3件: D00814 D00814, D01372 D01372, D07875 D07875 💬 |
GABRA1 19件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, SLC6A2, SLC6A4 💬 |
Calcium signaling pathway 10件: Calcium signaling pathway, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction |
006 1件: 6 💬 |
659 |
Dpa |
- |
- |
- |
- |
002 4件: 2, 6, 13, 85 💬 |
660 |
Dpa-714-pet/mri |
- |
- |
- |
- |
006 1件: 6 💬 |
661 |
Droxidopa |
Droxidopa |
1件: D01277 D01277 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
005 3件: 5, 6, 17 💬 |
662 |
Droxidopa 100 mg [northera] |
Droxidopa |
1件: D01277 D01277 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
663 |
Duloxetine |
Duloxetine |
2件: D01179 D01179, D07880 D07880 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6, 13 💬 |
664 |
Duloxetine hydrochloride |
Duloxetine |
2件: D01179 D01179, D07880 D07880 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 1件: 6 💬 |
665 |
Duodopa |
- |
- |
- |
- |
006 1件: 6 💬 |
666 |
Duodopa gel intestinale |
- |
- |
- |
- |
006 1件: 6 💬 |
667 |
Duodopa intestinal gel |
- |
- |
- |
- |
006 1件: 6 💬 |
668 |
Duodopa intestinalgel |
- |
- |
- |
- |
006 1件: 6 💬 |
669 |
Duodopa ld/cd 20/5 mg/ml |
- |
- |
- |
- |
006 1件: 6 💬 |
670 |
Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel |
- |
- |
- |
- |
006 1件: 6 💬 |
671 |
Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
672 |
Duodopa®intestinal gel |
- |
- |
- |
- |
006 1件: 6 💬 |
673 |
Dynacirc cr (isradipine) |
Isradipine |
1件: D00349 D00349 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
674 |
E2007 |
- |
- |
- |
- |
006 2件: 6, 144 💬 |
675 |
Ebixa |
- |
- |
- |
- |
002 3件: 2, 6, 13 💬 |
676 |
Ebixa® |
- |
- |
- |
- |
006 1件: 6 💬 |
677 |
Egcg |
Epigallocatechin gallate |
- |
- |
- |
006 9件: 6, 8, 13, 17, 28, 85, 113, 206, 299 💬 |
678 |
Elc200 |
- |
- |
- |
- |
006 1件: 6 💬 |
679 |
Eliprodil |
Eliprodil |
- |
- |
- |
006 1件: 6 💬 |
680 |
Elobixibat |
Elobixibat |
1件: D10796 D10796 💬 |
SLC10A2 1件: SLC10A2 💬 |
Bile secretion 1件: Bile secretion |
006 1件: 6 💬 |
681 |
Eltoprazine |
Eltoprazine |
- |
- |
- |
006 1件: 6 💬 |
682 |
Eltoprazine hcl |
Eltoprazine |
- |
- |
- |
006 1件: 6 💬 |
683 |
Eltoprazine hydrochloride |
Eltoprazine |
- |
- |
- |
006 1件: 6 💬 |
684 |
Emd 128130 |
- |
- |
- |
- |
006 2件: 6, 156 💬 |
685 |
Emd128130 |
- |
- |
- |
- |
006 1件: 6 💬 |
686 |
En |
- |
- |
- |
- |
006 3件: 6, 46, 97 💬 |
687 |
Ena713 |
- |
- |
- |
- |
006 2件: 6, 13 💬 |
688 |
Ena713b |
- |
- |
- |
- |
006 1件: 6 💬 |
689 |
Ent-01 |
- |
- |
- |
- |
006 1件: 6 💬 |
690 |
Entacapon |
- |
- |
- |
- |
006 1件: 6 💬 |
691 |
Entacapona |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
692 |
Entacapone |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 2件: 6, 17 💬 |
693 |
Entacapone 400mg oral dose |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 2件: 6, 17 💬 |
694 |
Entacapone and carbidopa |
Carbidopa |
2件: D00558 D00558, D00781 D00781 💬 |
COMT 2件: COMT, DDC 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
695 |
Entacapone inn |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
696 |
Entecapone |
- |
- |
- |
- |
006 1件: 6 💬 |
697 |
Epi-589 |
EPI-589 |
- |
- |
- |
002 2件: 2, 6 💬 |
698 |
Epi-743 200mg |
- |
- |
- |
- |
006 1件: 6 💬 |
699 |
Epi-743 400mg |
- |
- |
- |
- |
006 1件: 6 💬 |
700 |
Equal |
- |
- |
- |
- |
006 5件: 6, 13, 67, 86, 230 💬 |
701 |
Er cd-ld |
- |
- |
- |
- |
006 1件: 6 💬 |
702 |
Er tablet 100 mg azd3241 |
- |
- |
- |
- |
006 1件: 6 💬 |
703 |
Er tablet 25 mg azd3241 |
- |
- |
- |
- |
006 1件: 6 💬 |
704 |
Eradication of helcobacter pylori |
- |
- |
- |
- |
006 1件: 6 💬 |
705 |
Eradication therapy for h.pylori infection |
- |
- |
- |
- |
006 1件: 6 💬 |
706 |
Eradication therapy for helicobacter pylori |
- |
- |
- |
- |
006 1件: 6 💬 |
707 |
Erythromycin |
Erythromycin |
9件: D00140 D00140, D00851 D00851, D01361 D01361, D02009 D02009, D02184 D02184, D02523 D02523, D02524 D02524, D02525 D02525, D04054 D04054 💬 |
- |
- |
006 5件: 6, 36, 164, 228, 291 💬 |
708 |
Erythropoietin |
Erythropoietin |
1件: D03231 D03231 💬 |
EPOR 1件: EPOR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 9件: 2, 6, 13, 18, 22, 47, 70, 95, 96 💬 |
709 |
Erythropoietin human recombinant (eporh) |
Erythropoietin |
1件: D03231 D03231 💬 |
EPOR 1件: EPOR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
006 1件: 6 💬 |
710 |
Escitalopram |
Escitalopram |
3件: D02567 D02567, D07704 D07704, D07913 D07913 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
002 3件: 2, 6, 13 💬 |
711 |
Escitalopram oxalate |
Escitalopram |
3件: D02567 D02567, D07704 D07704, D07913 D07913 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 1件: 6 💬 |
712 |
Eszopiclone |
Eszopiclone |
1件: D02624 D02624 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 3件: 6, 13, 46 💬 |
713 |
Ethnodyne visio |
- |
- |
- |
- |
006 1件: 6 💬 |
714 |
Ethylmethylcarbamic acid 3-[(1s)-1-(dimethylamino)ethyl]phenyl ester (**see other 2 names below) |
- |
- |
- |
- |
006 1件: 6 💬 |
715 |
Exametazime |
Exametazime |
1件: D01109 D01109 💬 |
- |
- |
006 1件: 6 💬 |
716 |
Exelon |
- |
- |
- |
- |
006 2件: 6, 13 💬 |
717 |
Exelon 4.6 mg/24 h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
718 |
Exelon 9.5 mg/24 h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
719 |
Exelon patch |
- |
- |
- |
- |
006 1件: 6 💬 |
720 |
Exelon patch (rivastigmine transdermal system) |
Rivastigmine |
2件: D02558 D02558, D03822 D03822 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
721 |
Exelon path transdermal |
- |
- |
- |
- |
006 1件: 6 💬 |
722 |
Exelon ® |
- |
- |
- |
- |
006 1件: 6 💬 |
723 |
Exenatide |
Exenatide |
1件: D04121 D04121 💬 |
GLP1R 1件: GLP1R 💬 |
Insulin secretion 3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
006 4件: 6, 17, 193, 233 💬 |
724 |
Exenatide 10 micrograms |
Exenatide |
1件: D04121 D04121 💬 |
GLP1R 1件: GLP1R 💬 |
Insulin secretion 3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
006 1件: 6 💬 |
725 |
Exenatide 5 micrograms |
Exenatide |
1件: D04121 D04121 💬 |
GLP1R 1件: GLP1R 💬 |
Insulin secretion 3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
006 1件: 6 💬 |
726 |
Exenatide extended release 2mg (bydureon) |
Exenatide |
1件: D04121 D04121 💬 |
GLP1R 1件: GLP1R 💬 |
Insulin secretion 3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
006 1件: 6 💬 |
727 |
F-18 fpcit |
- |
- |
- |
- |
006 1件: 6 💬 |
728 |
Famotidine |
Famotidine |
1件: D00318 D00318 💬 |
HRH2 1件: HRH2 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
006 4件: 6, 46, 86, 98 💬 |
729 |
Fb-101 |
- |
- |
- |
- |
006 1件: 6 💬 |
730 |
Febuxostat |
Febuxostat |
1件: D01206 D01206 💬 |
XDH 1件: XDH 💬 |
Caffeine metabolism 5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
002 3件: 2, 6, 13 💬 |
731 |
Ferriprox |
- |
- |
- |
- |
006 2件: 6, 120 💬 |
732 |
Ferriprox 500 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
733 |
Ferrprox (deferiprone) |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
734 |
Fesoterodine |
Fesoterodine |
1件: D07226 D07226 💬 |
CHRM2 2件: CHRM2, CHRM3 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin |